Skip Navigation


NDT Advance Access originally published online on January 18, 2006
Nephrology Dialysis Transplantation 2006 21(5):1340-1347; doi:10.1093/ndt/gfk051
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/5/1340    most recent
gfk051v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Tsai, T.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Tsai, T.-J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Original Articles: Dialysis and Transplantation

Diltiazem suppresses collagen synthesis and IL-1ß-induced TGF-ß1 production on human peritoneal mesothelial cells

Cheng-Chung Fang1, Chung-Jen Yen2, Yung-Ming Chen2, Tzong-Shinn Chu2, Ming-Tsan Lin3, Ju-Yeh Yang2 and Tun-Jun Tsai2

Departments of 1 Emergency Medicine, 2 Internal Medicine and 3 Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

Correspondence and offprint requests to: Professor Tun-Jun Tsai, Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung Shan South Road, Taipei 100, Taiwan. Email: paul{at}ha.mc.ntu.edu.tw

Background. After long-term treatment with continuous ambulatory peritoneal dialysis (CAPD), some patients may develop peritoneal fibrosis. Peritoneal mesothelial cells (PMCs) participate in the inflammatory reactions in the peritoneal cavity, and transforming growth factor-ß1 (TGF-ß1) and interleukin-1ß (IL-1ß) are involved in peritoneal fibrosis. Diltiazem is used frequently in patients with CAPD to treat hypertension. The objectives of this study were to examine the effects of diltiazem on collagen- and IL-1ß-induced TGF-ß1 production on human PMCs and the signalling pathway of diltiazem in this induction.

Methods. Human PMCs were cultured from the enzymatic disaggregation of human omentum. Collagen synthesis was measured by [3H]proline incorporation into pepsin-resistant, salt-precipitated collagen. The expression of collagen I and III, and TGF-ß1 mRNA was evaluated by northern blotting. The production of TGF-ß1 by human PMCs was measured by immunoassay. The changes of intracellular calcium level after adding Fura-2-AM were measured by fluorescence spectrophotometry. Western blotting was used to assess mitogen-activated protein kinase (MAPK) signalling proteins.

Results. We found that diltiazem (<0.2 mM) inhibited collagen I and III mRNA expression and collagen syntheses on a dose-dependent basis. Diltiazem (0.2 mM) suppressed IL-1ß- (5 ng/ml) induced TGF-ß1 production on human PMCs at both the protein and mRNA levels. Diltiazem (0.2 mM) also inhibited IL-1ß- (5 ng/ml) induced collagen I and III mRNA expression. Intracellular calcium levels did not change after the treatment with diltiazem, IL-1ß or both. The IL-1ß-treated human PMCs increased phospho-JNK (stress-activated c-Jun N-terminal kinase) and phospho-p38 MAPK expression, while diltiazem could suppress this phenomenon.

Conclusions. Diltiazem suppressed collagen synthesis of human PMCs and inhibited IL-1ß-induced TGF-ß1 production on human PMCs. This signalling transduction may be through p38 MAPK and JNK pathways instead of intracellular calcium. These results suggest diltiazem to be a potential therapeutic regimen in preventing peritoneal fibrosis and support further in vivo studies.

Keywords: diltiazem; IL-1ß; mitogen-activated protein kinase; peritoneal mesothelial cell; signalling pathway; TGF-ß1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
L. S. Aroeira, A. Aguilera, J. A. Sanchez-Tomero, M. A. Bajo, G. del Peso, J. A. Jimenez-Heffernan, R. Selgas, and M. Lopez-Cabrera
Epithelial to Mesenchymal Transition and Peritoneal Membrane Failure in Peritoneal Dialysis Patients: Pathologic Significance and Potential Therapeutic Interventions
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2004 - 2013.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.